Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Unraveling the Role of miR-33a-5p in Bladder Cancer Progression: Clinical Significance and Functional Pathways.

Combinatorial chemistry & high throughput screening·2026

Same author

Innovations in Depression Diagnosis and Treatment: A Review of Biological, Cognitive, and Psychosocial Advances.

Current topics in medicinal chemistry·2026

Same author

CCNJL as a Prognostic Biomarker and Therapeutic Target in Cholangiocarcinoma.

Current medicinal chemistry·2026

Same author

Decoding Sarcoma Drug Resistance: From Molecular Mechanisms to Precision Interventions.

Anti-cancer agents in medicinal chemistry·2026

Same author

Research Progress on Desmoid Tumors: New Perspectives from Molecular Mechanisms to Clinical Management.

Anti-cancer agents in medicinal chemistry·2026

Same author

From Biomarker to Drug Target: Integrating ceRNA Networks and Pharmacogenomics to Reposition C5orf34 in Uterine Corpus Endometrial Cancer Therapy.

Current medicinal chemistry·2026

Search research articles

Related Experiment Video

Updated: Sep 17, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Exploring MFSD9: From Expression Patterns to Therapeutic Implications in LUAD.

Qian Wang¹, Meijuan Zhang², Yan Xiang¹

¹Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.

Current Medicinal Chemistry

|July 3, 2025

Summary

This summary is machine-generated.

Major Facilitator Superfamily Domain-containing Protein 9 (MFSD9) is overexpressed in lung adenocarcinoma (LUAD), indicating it is a potential prognostic biomarker and therapeutic target for improved patient outcomes.

Keywords:

Lung adenocarcinoma MFSD9 biomarker drug sensitivity.immune infiltration prognosis

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

The Soft Agar Colony Formation Assay

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Sep 17, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

The Soft Agar Colony Formation Assay

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

Area of Science:

Oncology
Molecular Biology
Bioinformatics

Background:

Lung adenocarcinoma (LUAD) is a major cause of cancer-related mortality.
Identifying novel biomarkers and therapeutic targets is crucial for improving LUAD patient prognosis and treatment strategies.

Purpose of the Study:

To investigate the role of Major Facilitator Superfamily Domain-containing Protein 9 (MFSD9) in LUAD.
To evaluate MFSD9 as a potential prognostic biomarker and therapeutic target in LUAD.

Main Methods:

Utilized The Cancer Genome Atlas (TCGA) dataset for comprehensive analysis of MFSD9 expression in LUAD.
Correlated MFSD9 expression with clinical outcomes, immune infiltration, tumor mutational burden (TMB), microsatellite instability (MSI), and drug sensitivity.
Validated findings using Human Protein Atlas (HPA), Gene Expression Omnibus (GEO) databases, and qRT-PCR.

Main Results:

MFSD9 was significantly overexpressed in LUAD, associated with poorer overall survival (OS) and progression-free survival (PFS).
MFSD9 serves as an independent prognostic factor in LUAD.
MFSD9 expression correlated with immune cell infiltration, immune checkpoint genes, TMB, MSI, mRNA expression-stemness index (mRNAsi), and inversely with sensitivity to zygosporin A and lovastatin.

Conclusions:

MFSD9 demonstrates potential as a prognostic biomarker and therapeutic target in LUAD.
MFSD9's involvement in immune modulation suggests its utility in immunotherapy strategies for LUAD.
Further functional validation is recommended to explore MFSD9's clinical applications in LUAD treatment.